title: Is there a heterozygote advantage for familial Mediterranean fever carriers against tuberculosis infections: speculations remain?
authors.forename: S
authors.initials: S
authors.lastname: Ozen
authors.forename: B
authors.initials: B
authors.lastname: Balci
authors.forename: S
authors.initials: S
authors.lastname: Ozkara
authors.forename: A
authors.initials: A
authors.lastname: Ozcan
authors.forename: E
authors.initials: E
authors.lastname: Yilmaz
authors.forename: N
authors.initials: N
authors.lastname: Besbas
authors.forename: M
authors.initials: M
authors.lastname: Ozguc
authors.forename: D L
authors.initials: DL
authors.lastname: Kastner
authors.forename: A
authors.initials: A
authors.lastname: Bakkaloglu
mesh_terms: D000293:Adolescent; D000328:Adult; D003598:Cytoskeletal Proteins; D010505:Familial Mediterranean Fever / Q000235:genetics*; D005260:Female; D006579:Heterozygote; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011506:Proteins / Q000235:genetics*; D000071198:Pyrin; D012641:Selection, Genetic; D014376:Tuberculosis / Q000235:genetics* / Q000517:prevention & control; D014421:Turkey
chemical_list: D003598:Cytoskeletal Proteins; C000604192:MEFV protein, human; D011506:Proteins; D000071198:Pyrin